Open Accessibility Menu

Mary Katherine Lawrence, MD

  • Carteret Medical Group Member
Affiliations American College of Endocrinologists-Fellow, Certified-International Society of Bone Densitometry, Medical Director, Broad Street Clinic, Chief of Staff-Carteret General Hospital-2011, Former Credentials Committee Chair, Member-Physicians for Social Responsibility
  • Board Certification
  • Endocrinology & Metabolism
  • Internal Medicine-American Board of Internal Medicine
  • Fellowship
  • UNC-Chapel Hill
  • Medical School
  • George Washington University School of Medicine
  • Residency
  • Vanderbilt University Hospitals
Medical Interests Research Interests:

As a principal investigator, Dr. Lawrence conducts clinical studies in promising new treatments for diabetes and associated conditions. Patients who participate in a clinical study can learn more about their disease and its treatment, contribute to medical knowledge, and take advantage of study-related visits and procedures at no cost.

Below is a list of some of the approved medications for which Dr. Lawrence has conducted studies.

  • Afrezza® rapid-acting inhaled insulin
  • Symlin® (pramlintide) for diabetic patients taking insulin
  • Glyset® (miglitol) to control blood glucose levels in Type 2 diabetes
  • Amaryl® (glimepiride) sulfonylurea for Type 2 diabetes
  • Pravachol® (pravastatin) to lower cholesterol
  • Januvia® (sitagliptin) for Type 2 diabetes
  • Bydureon ER® (exenatide) weekly injection for Type 2 diabetes
  • Farxiga® (dapagliflozin) for glycemic control in Type 2 diabetes
  • Ozempic® (semaglutide) weekly injection in Type 2 diabetes
  • Xolair® (omalizumab) for moderate to severe asthma
  • AndroGel® testosterone replacement therapy
  • PRINCIPAL INVESTIGATOR in all of the following:
  • Inhaled Insulin in Type 1 Diabetics
  • Renal Failure in Type 2 Diabetics
  • Cantata-02, SGLT 2 Inhibitor
  • GBBD, type 2 diabetes on insulin
  • Target Diabetic neuropathy, aldose reductase
  • Renal Insufficiency in Diabetes
  • Milly, Asthma
  • Drug Naive Type 2 Diabetes, SGLT inhibitor
  • Toccato: Rimonabontin Diabetes
  • E2008 Diabetic Neuropathy
  • E2007 Diabetic Neuropathy
  • Extra Xolair in Asthma
  • DPP-4 in Drug Naive Diabetes
  • CV-168 Drug Naive Type 2 Diabetes
  • Ascend Diabetic Nephropathy
  • Symlin in Type 1 and 2 Diabetes
  • IDAS-Inhaled Insulin in Asthma/COPD
  • IDAH-Inhaled Insulin in Type I DM
  • IDAP-Inhaled Insulin in Type II DM
  • DPP-4 Inhibitor in Diabetic Nephropathy
  • TREAT Anemia in Diabetic Nephropathy
  • Matrix Urinary Incontinence
  • Domperodine Trial Diabetic Gastroparesis
  • Trumpet-Hyperlipidemia
  • Smart Study-Asthma
  • Glimepiride in Type 2 Diabetes
  • Miglitol in Type 2 Diabetes
  • Bisphosphonates in Osteoporosis
  • Testosterone Replacement in Type 2 Diabetes
  • Pravastatin in Hyperlipidemia

Special Clinical Interests:

  • Diabetes and Thyroid Disease
  • Osteoporosis detection, prevention and treatment